{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:38:58Z","timestamp":1790797138810,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007771","name":"\u015al\u0105ski Uniwersytet Medyczny","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jim.2018.03.005","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T13:50:28Z","timestamp":1520603428000},"page":"112429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"475","author":[{"given":"\u0141ukasz","family":"S\u0119dek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prisca","family":"Theunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Sobral da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alita","family":"van der Sluijs-Gelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Mejstrikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gaipa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Sonsala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Twardoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elen","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Novakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Buracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques J.M.","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-3763","authenticated-orcid":false,"given":"Vincent H.J.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Szczepa\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.jim.2018.03.005_bb0005","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","article-title":"Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow","volume":"27","author":"Basso","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jim.2018.03.005_bb0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.seminoncol.2011.11.009","article-title":"Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle","volume":"39","author":"Br\u00fcggemann","year":"2012","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.jim.2018.03.005_bb0015","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.hoc.2009.07.010","article-title":"Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia","volume":"23","author":"Campana","year":"2009","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"4","key":"10.1016\/j.jim.2018.03.005_bb0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MOH.0b013e3283543d5c","article-title":"Minimal residual disease monitoring in childhood acute lymphoblastic leukemia","volume":"19","author":"Campana","year":"2012","journal-title":"Curr. Opin. Hematol."},{"issue":"7","key":"10.1016\/j.jim.2018.03.005_bb0025","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood.V97.7.2115","article-title":"Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia","volume":"97","author":"Chen","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jim.2018.03.005_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/7R6MU7R9YWJBY5V4","article-title":"Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia\/lymphoma: a single institution experience","volume":"127","author":"Chen","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.jim.2018.03.005_bb0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2002-01-0006","article-title":"Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jim.2018.03.005_bb0040","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","article-title":"New markers for minimal residual disease detection in acute lymphoblastic leukemia","volume":"117","author":"Coustan-Smith","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jim.2018.03.005_bb0045","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/leu.2012.231","article-title":"Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"27","author":"Denys","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jim.2018.03.005_bb0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cyto.b.20516","article-title":"Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOPBFM-ALL-FLOW-MRD-Study Group","volume":"78","author":"Dworzak","year":"2010","journal-title":"Cytometry B Clin. Cytom."},{"issue":"10","key":"10.1016\/j.jim.2018.03.005_bb0055","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow (NGF) for high-sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jim.2018.03.005_bb0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.leu.2403559","article-title":"Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection","volume":"19","author":"Gaipa","year":"2005","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jim.2018.03.005_bb0065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/cyto.b.21101","article-title":"Detection of minimal residual disease in pediatric acute lymphoblastic leukemia","volume":"84","author":"Gaipa","year":"2013","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.jim.2018.03.005_bb0070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/EDBK_175437","article-title":"Understanding the new WHO classification of lymphoid malignancies: why it's important and how it will affect practice","volume":"37","author":"Jaffe","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"9","key":"10.1016\/j.jim.2018.03.005_bb0075","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jim.2018.03.005_bb0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cyto.a.22581","article-title":"Quality assessment program for EuroFlow protocols: summary results of four-year (2010\u22122013) quality assurance rounds","volume":"87","author":"Kalina","year":"2015","journal-title":"Cytometry A"},{"issue":"2","key":"10.1016\/j.jim.2018.03.005_bb0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4149\/neo_2014_017","article-title":"Monitoring of minimal residual disease in acute leukemia by multiparametric flow cytometry","volume":"61","author":"Kusenda","year":"2014","journal-title":"Neoplasma"},{"issue":"3","key":"10.1016\/j.jim.2018.03.005_bb0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.leu.2401279","article-title":"Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL","volume":"13","author":"Lucio","year":"1999","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jim.2018.03.005_bb0095","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/sj.leu.2402150","volume":"15","author":"Lucio","year":"2001","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jim.2018.03.005_bb0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/pbc.22261","article-title":"Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry","volume":"54","author":"Mejstrikova","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.jim.2018.03.005_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/AJCP6VDBL4BRXRQA","article-title":"NRP-1\/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia","volume":"137","author":"Meyerson","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"issue":"25","key":"10.1016\/j.jim.2018.03.005_bb0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood-2012-11-468702","article-title":"Leukemia surfaceome analysis reveals new disease-associated features","volume":"121","author":"Mirkowska","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jim.2018.03.005_bb0115","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.hoc.2009.04.009","article-title":"Acute lymphoblastic leukemia","volume":"23","author":"Onciu","year":"2009","journal-title":"Hematol. Oncol. Clin. N. Am."},{"issue":"1","key":"10.1016\/j.jim.2018.03.005_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pcl.2007.11.002","article-title":"Biology and treatment of acute lymphoblastic leukemia","volume":"55","author":"Pieters","year":"2008","journal-title":"Pediatr. Clin. N. Am."},{"issue":"2","key":"10.1016\/j.jim.2018.03.005_bb0125","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jim.2018.03.005_bb0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/cytob.21176","article-title":"The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?","volume":"86","author":"S\u0119dek","year":"2014","journal-title":"Cytometry B Clin. Cytom."},{"issue":"3","key":"10.1016\/j.jim.2018.03.005_bb0135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/leu.2013.354","article-title":"CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage","volume":"28","author":"Slamova","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jim.2018.03.005_bb0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cyto.a.21162","article-title":"CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry","volume":"81","author":"Solly","year":"2012","journal-title":"Cytometry A"},{"issue":"4","key":"10.1016\/j.jim.2018.03.005_bb0145","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.leu.2404603","article-title":"Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?","volume":"21","author":"Szczepa\u0144ski","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jim.2018.03.005_bb0150","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1521-6926(03)00086-0","article-title":"Classification systems for acute and chronic leukaemias","volume":"16","author":"Szczepa\u0144ski","year":"2003","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"3","key":"10.1016\/j.jim.2018.03.005_bb0155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jim.2018.03.005_bb0160","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.jim.2018.03.005_bb0165","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jim.2018.03.005_bb0170","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.3109\/10428194.2015.1070153","article-title":"The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia","volume":"57","author":"Wang","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.jim.2018.03.005_bb0175","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2011.174","article-title":"CD73 (5\u2032-nucleotidase) expression has no prognostic value in children with acute lymphoblastic leukemia","volume":"25","author":"Wieten","year":"2011","journal-title":"Leukemia"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175917301266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175917301266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:26:40Z","timestamp":1762205200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175917301266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"alternative-id":["S0022175917301266"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2018.03.005","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2018.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112429"}}